The new patent will cover solid crystal forms of SCO-101, which includes the form of the compound that Scandion expects to commercialize.
The new patent covers solid crystal and amorphous forms of SCO-101, which includes the form of the compound that Scandion expects to commercialize. Expiring in 2042, the patent will extend the potential exclusivity period for SCO-101 in its expected commercial crystal form and significantly strengthen the intellectual property portfolio covering it. This may allow Scandion to expand the development of SCO-101 into new indications and drug combinations, potentially making a future treatment available to more patients.
SCO-101 is currently being clinically developed as a combination treatment for metastatic colorectal cancer (mCRC) and pancreatic cancer. Just last week, Scandion presented impressive new overall survival data from its CORIST trial, studying SCO-101 as a combination treatment of mCRC, to be further confirmed in a larger clinical trial.
“The granting of this patent is an important component of our strategy to become one of the leaders in the development of drugs that target cancer drug resistance. It puts us in the unique position of having close to 20 years of patent protection on a compound already in clinical development,” said
Today, cancer drug resistance continues to constitute a huge unmet medical need. Scandion believes that SCO-101 can revert cancer’s resistance to treatments like chemotherapy thereby making the treatments work better and prolonging the lives of patients with end-stage diseases such as mCRC.
The formal grant of the patent follows the positive opinion issued by the EPO in
The patent, entitled, “THERMODYNAMICALLY STABLE FORM OF SCO-101” is effective
For further information please contact:
Johnny Stilou, CFO
Phone: +45 2960 3532
E-mail: jos@scandiononcology.com
The information was provided by the contact person above for publication on
Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.
Scandion is based in
Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.
© Modular Finance, source